HRP20210551T1 - Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije - Google Patents
Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije Download PDFInfo
- Publication number
- HRP20210551T1 HRP20210551T1 HRP20210551TT HRP20210551T HRP20210551T1 HR P20210551 T1 HRP20210551 T1 HR P20210551T1 HR P20210551T T HRP20210551T T HR P20210551TT HR P20210551 T HRP20210551 T HR P20210551T HR P20210551 T1 HRP20210551 T1 HR P20210551T1
- Authority
- HR
- Croatia
- Prior art keywords
- mixture
- crystallized particles
- temperature
- target temperature
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041341P | 2014-08-25 | 2014-08-25 | |
| EP15836431.5A EP3185867B1 (en) | 2014-08-25 | 2015-08-24 | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
| PCT/US2015/046525 WO2016032950A1 (en) | 2014-08-25 | 2015-08-24 | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210551T1 true HRP20210551T1 (hr) | 2021-08-20 |
Family
ID=55347322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210551TT HRP20210551T1 (hr) | 2014-08-25 | 2015-08-24 | Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10064859B2 (https=) |
| EP (2) | EP3185867B1 (https=) |
| JP (2) | JP6591546B2 (https=) |
| CN (2) | CN111454207B (https=) |
| AU (2) | AU2015306910B2 (https=) |
| CA (1) | CA2959329C (https=) |
| CY (1) | CY1124058T1 (https=) |
| DK (1) | DK3185867T3 (https=) |
| ES (2) | ES2862098T3 (https=) |
| HR (1) | HRP20210551T1 (https=) |
| HU (1) | HUE054641T2 (https=) |
| IL (1) | IL250661B (https=) |
| LT (1) | LT3185867T (https=) |
| MA (2) | MA55917A (https=) |
| PL (1) | PL3185867T3 (https=) |
| PT (1) | PT3185867T (https=) |
| RS (1) | RS61709B1 (https=) |
| SI (1) | SI3185867T1 (https=) |
| SM (1) | SMT202100212T1 (https=) |
| WO (1) | WO2016032950A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6654042B2 (ja) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| WO2016032950A1 (en) * | 2014-08-25 | 2016-03-03 | Alkermes Pharma Ireland Limited | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
| WO2016181406A1 (en) * | 2015-05-08 | 2016-11-17 | Davuluri Ramamohan Rao | Improved process for the preparation of aripiprazole with reduced particle size |
| WO2018104953A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate |
| US20200140410A1 (en) | 2017-07-28 | 2020-05-07 | Interquim, S.A. | Process for the preparation of aripiprazole lauroxil |
| CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN113105389B (zh) * | 2021-04-16 | 2022-04-08 | 江苏海洋大学 | 一种阿立哌唑药物共晶及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| ATE411797T2 (de) * | 2003-10-23 | 2008-11-15 | Otsuka Pharma Co Ltd | Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren |
| BRPI0821408A2 (pt) | 2007-12-19 | 2015-06-16 | Janssen Pharmaceutica Nv | Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação |
| US20110003823A1 (en) | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
| LT2445502T (lt) | 2009-06-25 | 2017-09-25 | Alkermes Pharma Ireland Limited | Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui |
| WO2012077134A1 (en) * | 2010-12-07 | 2012-06-14 | Ind-Swift Laboratories Limted | Process for preparing aripiprazole polymorphs |
| WO2012094648A1 (en) * | 2011-01-07 | 2012-07-12 | Neodyne Biosciences, Inc. | Wound or skin treatment devices and methods |
| BR112013023847B1 (pt) * | 2011-03-18 | 2021-02-23 | Alkermes Pharma Ireland Limited | composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas |
| CA2867121C (en) * | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| JP6654042B2 (ja) * | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | 貯蔵安定性が改善された医薬組成物 |
| WO2016032950A1 (en) * | 2014-08-25 | 2016-03-03 | Alkermes Pharma Ireland Limited | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
-
2015
- 2015-08-24 WO PCT/US2015/046525 patent/WO2016032950A1/en not_active Ceased
- 2015-08-24 CN CN202010375290.3A patent/CN111454207B/zh active Active
- 2015-08-24 DK DK15836431.5T patent/DK3185867T3/da active
- 2015-08-24 PL PL15836431T patent/PL3185867T3/pl unknown
- 2015-08-24 EP EP15836431.5A patent/EP3185867B1/en active Active
- 2015-08-24 JP JP2017530956A patent/JP6591546B2/ja active Active
- 2015-08-24 SM SM20210212T patent/SMT202100212T1/it unknown
- 2015-08-24 SI SI201531576T patent/SI3185867T1/sl unknown
- 2015-08-24 PT PT158364315T patent/PT3185867T/pt unknown
- 2015-08-24 MA MA055917A patent/MA55917A/fr unknown
- 2015-08-24 RS RS20210433A patent/RS61709B1/sr unknown
- 2015-08-24 MA MA40480A patent/MA40480B1/fr unknown
- 2015-08-24 CA CA2959329A patent/CA2959329C/en active Active
- 2015-08-24 US US14/833,638 patent/US10064859B2/en active Active
- 2015-08-24 ES ES15836431T patent/ES2862098T3/es active Active
- 2015-08-24 EP EP21150116.8A patent/EP3865476B1/en active Active
- 2015-08-24 HU HUE15836431A patent/HUE054641T2/hu unknown
- 2015-08-24 HR HRP20210551TT patent/HRP20210551T1/hr unknown
- 2015-08-24 ES ES21150116T patent/ES2994850T3/es active Active
- 2015-08-24 LT LTEP15836431.5T patent/LT3185867T/lt unknown
- 2015-08-24 CN CN201580057857.XA patent/CN107106556B/zh active Active
- 2015-08-24 AU AU2015306910A patent/AU2015306910B2/en active Active
-
2017
- 2017-02-19 IL IL250661A patent/IL250661B/en active IP Right Grant
-
2018
- 2018-07-24 US US16/043,721 patent/US10478434B2/en active Active
-
2019
- 2019-09-18 JP JP2019169473A patent/JP2019210296A/ja active Pending
- 2019-10-08 US US16/595,608 patent/US10973816B2/en active Active
-
2020
- 2020-11-04 AU AU2020264303A patent/AU2020264303B2/en active Active
-
2021
- 2021-03-24 US US17/211,352 patent/US11883394B2/en active Active
- 2021-04-13 CY CY20211100318T patent/CY1124058T1/el unknown
-
2023
- 2023-12-18 US US18/543,767 patent/US20240245676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210551T1 (hr) | Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije | |
| HRP20210675T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20211666T1 (hr) | Oblici soli lumateperon ditozilata u krutom stanju | |
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20160886T1 (hr) | Besilatna i tosilatna sol derivata dihidrokinazolina i njihova upotreba kao protuvirusna sredstva | |
| JP2017526747A5 (https=) | ||
| MX389304B (es) | Producto farmaceutico. | |
| SG10201806565SA (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| HRP20211782T1 (hr) | Derivati indola kao inhibitori replikacije denga virusa | |
| HRP20210183T1 (hr) | 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate | |
| MD3313851T2 (ro) | Noi derivați hidroxiester, procedeu pentru prepararea lor și compoziții farmaceutice care îi conțin | |
| HRP20160813T1 (hr) | Natrijeve i kalcijeve soli derivata dihidrokinazolina i njihova upotreba kao antivirusna sredstva | |
| HRP20201644T1 (hr) | Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba | |
| HRP20211282T1 (hr) | Oksisteroli i postupci njihovog korištenja | |
| SI3416966T1 (sl) | Postopek za pripravo (7-((4-fenil-5-alkoksikarbonil-2-tiazol-2-il-1,4- dihidropirimidin-6-il)metil)-3-okso-5,6,8,8a-tetrahidro-1h-imidazo(1,5a) pirazin-2-il)alkil karboksilnih kislin | |
| JP6655608B2 (ja) | ６−（（６，７−ジメトキシキナゾリン−４−イル）オキシ）−ｎ，２−ジメチルベンゾフラン−３−カルボキサミドの結晶形 | |
| FI3206692T3 (fi) | Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja | |
| HRP20192286T1 (hr) | Hidroksieitil sulfonat od ciklina ovisnog inhibitora kinaze proteina, njegov kristalni oblik, i postupak njegovog dobivanja | |
| WO2016166720A3 (en) | Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives | |
| HRP20220234T1 (hr) | Kristalni oblici | |
| HRP20171707T1 (hr) | Postupak proizvodnje rivaroksabana | |
| RU2019106531A (ru) | Кристалл соли производного хиназолина | |
| MA35002B1 (fr) | Forme cristalline delta du sel d'arginine du périndopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| EP3519388A4 (en) | METHOD FOR PRODUCING BOSCALID ANHYDRATE FORM I AND BOSCALID ANHYDRATE FORM II | |
| HRP20191716T1 (hr) | Čvrste oralne formulacije koje sadrže čvrste disperzije talina organskih kiselina u ksilitolu |